Tg launches 1 Bio, single-use biopharma scale-up hub

The IT Minister announced over `200 crore in new infrastructure upgrades by TGIIC

Hyderabad: In a major boost to India’s biologics and next-generation therapeutics ecosystem, Telangana, on Monday inaugurated 1 Bio, the nation’s first single-use bioprocess design and scale-up facility, marking a pivotal expansion of the Genome Valley innovation cluster. The facility was unveiled by Telangana’s Minister for IT, Electronics & Communications, and Industries & Commerce D Sridhar Babu, who described the launch as the “next wave of growth and leadership” for India’s biopharma sector.

Speaking at the event, Minister Sridhar Babu said, “As Genome Valley marks 25 years, we are setting the course for its next 25 years. 1 Bio is one of India’s most important steps toward democratising access to biologics scale-up and accelerating the journey from discovery to clinical readiness. With this facility, innovations can now advance to pilot and clinical stages in Hyderabad faster, more predictably, and at lower cost.”

To prepare Genome Valley for its next phase of expansion, the Minister announced over Rs200 crore in new infrastructure upgrades by TGIIC, including road widening, new greenfield roads, power augmentation, and landscaping and streetscaping improvements to enhance connectivity and ensure robust utility services within the cluster.

Special Chief Secretary (Industries & ITE&C) Sanjay Kumar highlighted Telangana’s dominant role in national and global life sciences output, noting that the State contributes 40 per cent of India’s pharma production and one-third of global vaccine supply. He said 1 Bio strengthens this leadership by giving innovators access to world-class bioprocess development capacity.

Related Posts

Unapproved drops for dry eyes pose risks: Govt

NEW DELHI: Flagging that certain yet-to-be-approved dry eye relief drops are being sold in the market, the central drugs regulator has asked states to cancel any permissions granted for these…

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Unapproved drops for dry eyes pose risks: Govt

Unapproved drops for dry eyes pose risks: Govt

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

Govt highlights multi-layer framework to curb misleading advertisements

Govt highlights multi-layer framework to curb misleading advertisements

Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

Study finds rising resistance to a last-resort antibiotic in Africa

Study finds rising resistance to a last-resort antibiotic in Africa